Dentsply Sirona reported third‑quarter 2025 results on November 6, 2025, with net sales of $904 million, a 5.0 % decline from the same period in 2024. Foreign‑currency movements added roughly $28 million to sales, partially offsetting the decline. A $263 million impairment charge related to goodwill and intangible assets in the Orthodontic and Implant Solutions and Connected Technology Solutions segments pushed the company into a net loss of $427 million, or $2.14 per share.
Despite the sales decline, the company beat the consensus revenue estimate of $901.59 million by $2.41 million, a 0.27 % upside. The beat was driven by strong performance in the Wellspect Healthcare segment, which grew 9.3 % in constant currency, and by modest gains in Connected Technology Solutions. In contrast, the Orthodontic and Implant Solutions segment saw a 17.1 % drop in constant currency, reflecting weaker demand for implants and orthodontic products in the U.S. market.
Adjusted earnings per diluted share fell to $0.37, missing the consensus estimate of $0.45 by $0.08, or 17.8 %. The miss was largely attributable to the one‑time impairment charge and ongoing restructuring costs, which eroded operating income. Lower volumes in key product categories and continued pressure on the U.S. business further compressed margins, leaving the company unable to offset the impairment impact.
Management revised its full‑year outlook, projecting net sales of $3.6 billion to $3.7 billion and adjusted EPS of $1.60. The guidance reflects the Return‑to‑Growth action plan, which focuses on cost discipline, digital platform expansion, and strategic investments in high‑growth areas. The revised outlook also incorporates the expected impact of tariffs and foreign‑currency fluctuations, signaling a cautious but steady view of the company’s near‑term performance.
CEO Daniel T. Scavilla emphasized the need for “bold change” and “moving faster and acting bolder to reshape the customer experience.” He highlighted the Return‑to‑Growth plan as a comprehensive strategy to improve performance over the next 24 months. The company also announced leadership changes, including the departure of CFO Matt Garth and the appointment of Aldo Denti as Chief Commercial Officer, underscoring its commitment to transformation.
Investors reacted negatively to the earnings release, citing the EPS miss, lower guidance, and the substantial impairment charge as key concerns. The company’s ongoing challenges in the U.S. market and the need for tangible evidence of improvement in future quarters were also highlighted as headwinds.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.